Monday, 25 Sep 2017

Biologic/Novel Rx

Datesort ascending Type Title Save
07 Dec 2016 News Nonsignificant CV Risk with Actemra vs Enbrel
02 Dec 2016 News Is ABT-494 the Next JAK Inhibitor?
02 Dec 2016 Social Tofacitinib is not associated with a higher risk of malignancy. https://t.co/zInnHORI46
29 Nov 2016 Social Good, basic overview of Biosimilars. https://t.co/N0hE8xL8Ga
23 Nov 2016 Social RT @RWCSmtg: Jaknibs inhibit widely a cross a range of cytokines. https://t.co/iW2zjjefdg https://t.co/ThHnz3b1Of
22 Nov 2016 Social RT @DrPetryna: Sarilumab (IL6R) superior to Humira in MONARCH phase 3 trial. neutropenia &abn LFT > with sarilumab https://t.co/2Rwxz8hiZQ…
21 Nov 2016 News Ustekinumab Effective and Safe in Crohn's Colitis
17 Nov 2016 Social RT @DrAiLynTan: Great slide on comparing biologic therapy in #rheumatoidarthritis v #Crohns v #ulcerativecolitis via @JoseCamposMD #ACR16 h…
17 Nov 2016 Social RT @AngusWorthing: Dr Fratazzi on #biosimilars switching trials: must be 2 way (ie alternating) for interchangeability; & improve patient r…
17 Nov 2016 Social RT @CCalabreseDO: Dual cytokine inhibition with ABT-122 (targets TNFa and IL-17) for RA. check out abstract 3225. Genovese, et al. #ACR16 @…
16 Nov 2016 Social RT @rachelthuston: TCZ for clinical remission in GCA but doesn't fully suppress MR signals of vessel inflammation #ACR16 @RheumNow https://…
16 Nov 2016 Social RT @CCalabreseDO: Meaningful benefits in fatigue & HRQoL for SLE pts on long-term belimumab. Strand, et al. Abstract 3235 #ACR16 @RheumNow
13 Nov 2016 News Two New Biologics for Polyarticular JIA
02 Nov 2016 News Decreased CD4 T Cells with Rituximab Infusions
22 Oct 2016 Social SURPRISE study 223 RA MTX-IR pts Rx w/ TCZ+MTX or TCZ- earlier DAS28 Resp & less Xray damage w/ addon vs switch Rx. https://t.co/HCsbfjdqtH
17 Oct 2016 Slide of the day New Biosimilars 2016: Many Indications Based on Few RCTs
13 Oct 2016 Social Global biosimilars sales = 3.5 billion in 2015; poised to reach $15.6 billion by 2022. https://t.co/TATv2rgYTM
10 Oct 2016 Social Phase II ACCLAIM small trial fails to show significant benefit/safety of Abatacept in Multiple sclerosis (42 pts) https://t.co/GeU5XnhePt
06 Oct 2016 News Biosimilar Reports – October 2016
04 Oct 2016 News Pharma Points Blame at PBMs